Wilzin Recordati Rare Diseases · Authorised · authorised 12 Oct 2004 · ATC A16AX05
Therapeutic indication (EMA)
Treatment of Wilson's disease.
Active substance
Zinc
- EMA 1
- Health Canada 4
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MICRO ZN | 00787000 | 5 MG / ML | SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| MICRO ZN | 00787019 | 1 MG / ML | SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| ZINC SULFATE INJECTION, USP | 02532972 | 1 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| ZINC SULFATE INJECTION, USP | 02532980 | 5 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.